Young Therapeutics

Young Therapeutics is a private U.S. biotechnology company developing first-in-class therapies to prevent ischemia-reperfusion injury, a major cause of tissue damage in heart attack, transplantation, and cardiac procedures. The company is centered on inhibitors of protein kinase C isoforms designed to block the generation of reactive oxygen species during reperfusion rather than scavenging radicals after damage has begun. Its disclosed pipeline includes YT-001, YT-002, and YT-004, with preclinical work in myocardial ischemia-reperfusion and kidney transplant settings. Young Therapeutics appears to be grant-funded and very early stage, with NIH/SBIR support and orphan designation reported for a kidney transplant-related program. The company was founded by Lindon H. Young and is based in Philadelphia, Pennsylvania.